ArticleHaematologica2022
Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma.
Article in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II study.British journal of cancer · 2024Trial
- End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.International journal of hematology · 2024Trial
- Baseline FDG PET/CT SUVmax predicts POD24 and progression-free survival in newly diagnosed follicular lymphoma.Annals of nuclear medicine · 2026Article
- A deep learning PET/CT biomarker for early progression (POD24) and survival stratification in follicular lymphoma: a multicenter study.European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Early prognostic stratification of follicular lymphoma through ¹⁸F-FDG PET/CT tumor metabolic parameters and clinical characteristics.EJNMMI research · 2026Article
- Lymph node disease in 2-deoxy-2-fluorodeoxyglucose positron emission tomography/computed tomography imaging: Advances in artificial intelligence-driven automatic segmentation and precise diagnosis.World journal of clinical oncology · 2025Review
- Patients with follicular lymphoma should be treated according to baseline PET-CT findings with targeted re-biopsy.Annals of hematology · 2025Article
- Multicenter evaluation of predictive clinical and imaging factors for pathological response in non-small cell lung cancer patients treated with neoadjuvant chemotherapy and immune checkpoint inhibitors.Cancer immunology, immunotherapy : CII · 2025Article
- Integration of PET/CT parameters and a clinical variable to predict the risk of progression of disease within 24 months (POD24) in follicular lymphoma.Quantitative imaging in medicine and surgery · 2025Article
- Metabolic-immune axis in the tumor microenvironment: a new strategy for prognostic assessment and precision therapy in DLBCL and FL.Frontiers in immunology · 2025Review
- Personalised therapy in follicular lymphoma - is the dial turning?Hematological oncology · 2024Review
- Involvement of spleen is associated with shorter survival in patients with angioimmunoblastic T cell lymphoma.Journal of cancer research and clinical oncology · 2023Article
- Diagnostic and prognostic value of pretreatment PET/CT in extranodal natural killer/T-cell lymphoma: a retrospective multicenter study.Journal of cancer research and clinical oncology · 2023Article
- Evaluation of Semiautomatic and Deep Learning-Based Fully Automatic Segmentation Methods on [Journal of digital imaging · 2023Article
- Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas.Diagnostics (Basel, Switzerland) · 2022Article
- Improving the prognostic ability of PET/CT SUVmax to identify follicular lymphoma with early treatment failure.American journal of cancer research · 2022Article
- Significance of initial, interim and end-of-therapyCancer cell international · 2021Article
- Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma.Blood advances · 2021Article
- High Basal Maximal Standardized Uptake Value (SUVCancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Follicular lymphoma (FL) is the most common indolent lymphoma. Despite the clear benefit of CD20-based therapy, a subset of FL patients still progress to aggressive lymphoma. Thus, identifying early biomarkers that incorporate PET metrics could be helpful to identify patients with a high risk of treatment failure with Rituximab. We retrospectively included a total of 132 untreated FL patients separated into training and validation cohorts. Optimal threshold of baseline SUVmax was first determined in the training cohort (n=48) to predict progression-free survival (PFS). The PET results were investigated along with the tumor and immune microenvironment, which were determined by immunochemistry and transcriptome studies involving gene set enrichment analyses and immune cell deconvolution, together with the tumor mutation profile. We report that baseline SUVmax >14.5 was associated with poorer PFS than baseline SUVmax ≤14.5 (HR=0.28; p=0.00046). Neither immune T-cell infiltration nor immune checkpoint expression were associated with baseline PET metrics. By contrast, FL samples with Ki-67 staining ≥10% showed enrichment of cell cycle/DNA genes (p=0.013) and significantly higher SUVmax values (p=0.007). Despite similar oncogenic pathway alterations in both SUVmax groups of FL samples, 4 out of 5 cases harboring the infrequent FOXO1 transcription factor mutation were seen in FL patients with SUVmax >14.5. Thus, high baseline SUVmax reflects FL tumor proliferation and, together with Ki-67 proliferative index, can be used to identify patients at risk of early relapse with R-chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.